Hormonal
Women experience a significantly lower efficacy-to-tolerability ratio than men when treated with GLP-1 receptor agonists, characterized by disproportionately higher rates of persistent nausea and vomiting relative to weight loss.
If you are a woman taking a GLP-1 medication like semaglutide or tirzepatide, you are statistically more likely to experience nausea and vomiting than a man taking the same drug, even if you lose more weight. This is not a failure of willpower but a biological difference in how your body processes the drug, likely driven by estrogen levels. Discussing this with your provider may lead to strategies like slower dose escalation or phase-specific dosing to manage side effects.
We find that for both semaglutide and tirzepatide, women lose more weight (Fig. 1C) and experience a 2.5-fold higher rate of nausea and vomiting than men (Fig. 1D)... When comparing the ratio of weight loss to adverse event rates we find that women experience disproportionately more adverse events (i.e. nausea and vomiting) than men per kilogram of weight lost (Fig. 1E).
Why this rating
Strong evidence combining real-world EMR data with consistent preclinical findings in rats and mice, though causality in humans is correlational.
Source
Sex differences in GLP-1 signaling across species
Thomas Roseberry et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025
DOI 10.1101/2025.03.17.643822
More from this paper
- Females exhibit higher GLP-1 receptor (GLP1R) expression in specific brain regions (PBN, AP/NTS) involved in processing aversive stimuli, which may explain their heightened sensitivity to GLP-1 agonist-induced nausea.Strong
- Higher circulating estrogen levels in women are predictive of increased rates of nausea and vomiting when taking GLP-1 receptor agonists, and estrous cycle phase modulates drug sensitivity in female mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →